LYMPHOID ORGANS AND THEIR CELLS UNDER THE INFLUENCE OF INTERLEUKIN-2



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review of the current literature shows that interleukin-2 (IL-2) stimulates proliferation and functional activity of Т- and B-cells from central and peripheral lymphoid organs, as well as the macrophage functions. IL-2 influence is more expressed when it acts on the cells, activated previously; besides there is a possibility of the restoration of lymphoid organ functions which were previously suppressed as a result of influence of cytostatic drugs or ionizing radiation. On this activation of immune cells the application of IL-2 for treatment of inflammatory and oncologic processes is based. The realization of the further researches of a ratio of cell subpopulations in lymphoid organs with use of advanced achievements of immunohistochemical staining and modern methods of morphology is necessary in the time of treatment of various pathological processes by IL-2.

About the authors

I V Mayborodin

E I Strel'tsova

O A Zarubenkov

D V Egorov

A I Shevela

I V Maiborodin

The Center of Modern Medical Technologies, RAS SB Scientific Research Institute of Chemical Biology and Fundamental Medicine

The Center of Modern Medical Technologies, RAS SB Scientific Research Institute of Chemical Biology and Fundamental Medicine

Ye I Strel'tsova

The Center of Modern Medical Technologies, RAS SB Scientific Research Institute of Chemical Biology and Fundamental Medicine

The Center of Modern Medical Technologies, RAS SB Scientific Research Institute of Chemical Biology and Fundamental Medicine

O A Zarubenkov

The Center of Modern Medical Technologies, RAS SB Scientific Research Institute of Chemical Biology and Fundamental Medicine

The Center of Modern Medical Technologies, RAS SB Scientific Research Institute of Chemical Biology and Fundamental Medicine

D V Yegorov

The Center of Modern Medical Technologies, RAS SB Scientific Research Institute of Chemical Biology and Fundamental Medicine

The Center of Modern Medical Technologies, RAS SB Scientific Research Institute of Chemical Biology and Fundamental Medicine

A I Shevela

The Center of Modern Medical Technologies, RAS SB Scientific Research Institute of Chemical Biology and Fundamental Medicine

The Center of Modern Medical Technologies, RAS SB Scientific Research Institute of Chemical Biology and Fundamental Medicine

References

  1. Агеев Н.Л., Шамрай Н.А., Овечкин А.В. и др. Ронколейкин в лечении больных с гнойно-хирургической патологией: предварительные результаты рандомизированных, двойных-слепых, плацебо-контролируемых клинических испытаний. Мед. иммунология, 2001, т. 3, № 2, с. 301.
  2. Останин А.А., Зайнутдинов Ю.Г., Стрельцова Е.И. и др. Хирургический сепсис. II. Эффективность иммунотерапии рекомбинантным интерлейкином-2. Вестн. хир., 2002, т. 161, № 4, с. 79-84.
  3. Семенова-Кобзарь Р.А., Кушко Л.Я., Юдин В.М. и др. Влияние экзогенного интерлейкина-2 на функциональную активность иммунокомпетентных клеток мышей с перевивными опухолями. Экспер. онкол., 1982, т. 8, № 2, с. 39-42.
  4. Amu S., Gjertsson I., Tarkowski A. and Brisslert M. B-cell CD25 expression in murine primary and secondary lymphoid tissue. Scand. J. Immunol., 2006, v. 64, № 5, p. 482-492.
  5. An W. Comparative study on cytotoxicity of lymphocytes from different tissues in laryngeal cancer. Zhonghua Er Bi Yan Hou Ke Za Zhi, 1993, v. 28, № 5, p. 292-294, 314-315.
  6. Applegate K.G., Balch C.M. and Pellis N.R. In vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumor-infiltrating lymphocytes. Cancer Res., 1990, v. 50, № 22, p. 7153-7158.
  7. Arpin C., Dechanet J., Kooten van C. et al. Generation of memory B cells and plasma cells in vitro. Science, 1995, v. 268, № 5211, p. 720-722.
  8. Asahina M., Goryo M., Davis W.C. and Okada K. Immunohistological study on bovine lymph node using monoclonal antibodies to interleukin-2 receptor. Vet. Immunol. Immunopathol., 1996, v. 52, № 4, p. 411-413.
  9. Bonilla F., Alvarez-Mon M., Merino F. et al. Interleukin-2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients. Cancer, 1988, v. 61, № 4, p. 629-634.
  10. Cheever M.A., Thompson J.A., Kern D.E. and Greenberg P.D. Interleukin-2 administered in vivo induces the growth and augments the function of cultured T cells in vivo. J. Biol. Response Mod., 1984, v. 3, № 5, p. 462-467.
  11. Collins R.A. and Oldham G. Recombinant human interleukin 2 induces proliferation and immunoglobulin secretion by bovine B-cells: tissue differences and preferential enhancement of immunoglobulin A. Vet. Immunol. Immunopathol., 1993, v. 36, № 1, p. 31-43.
  12. Critchfield J.M., Zuniga-Pflucker J.C. and Lenardo M.J. Parameters controlling the programmed death of mature mouse T lymphocytes in high-dose suppression. Cell. Immunol., 1995, v. 160, № 1, p. 71-78.
  13. Darrow T.L., Quinn-Allen M.A., Crowley N.J. and Seigler H.F. Modulation of in vitro autologous melanoma-specific cytotoxic T-cell responses by phorbol dibutyrate and ionomycin. Cell. Immunol., 1990, v. 125, № 2, p. 508-517.
  14. Demaison C., Fiette L., Blanchetiere V. et al. IL-2 receptor alpha-chain expression is independently regulated in primary and secondary lymphoid organs. J. Immunol., 1998, v. 161, № 4, p. 1977-1982.
  15. D'Souza W.N. and Lefrancois L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J. Immunol., 2003, v. 171, № 11, p. 5727-5735.
  16. Duke R.C. and Cohen J.J. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. Lymphokine Res., 1986, v. 5, № 4, p. 289-299.
  17. Ettinghausen S.E., Lipford E.H. 3rd, Mule J.J. and Rosenberg S.A. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. J. Immunol., 1985, v. 135, № 2, p. 1488-1497.
  18. Garcia-Tunon I., Ricote M., Ruiz A. et al. Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res., 2004, v. 6, № 1, p. R1-R7.
  19. Gez E., Rubinov R., Gaitini D. et al. Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the rambam and linn medical centers, Haifa, Israel. J. Chemother., 2007, v. 19, № 1, p. 79-84.
  20. Hancock W.W., Kobzik L., Colby A.J. et al. Detection of lymphokines and lymphokine receptors in pulmonary sarcoidosis. Immunohistologic evidence that inflammatory macrophages express IL-2 receptors. Am. J. Pathol., 1986, v. 123, № 1, p. 1-8.
  21. Hofman F.M., Modlin R.L., Bhoopat L. and Taylor C.R. Distribution of cells bearing the Tac antigen during ontogeny of human lymphoid tissue. J. Immunol., 1985, v. 134, № 6, p. 3751-3755.
  22. Hoon D.S., Bowker R.J. and Cochran A.J. Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res., 1987, v. 47, № 6, p. 1529-1533.
  23. Indrova M., Bubenik J., Jakoubkova J. et al. Subcutaneous interleukin-2 in combination with vinblastine for metastatic renal cancer: cytolytic activity of peripheral blood lymphocytes. Neoplasma, 1994, v. 41, № 4, p. 197-200.
  24. Korcakova L. and Holub M. Lymph node activating factor from mixed cultures of allogeneic lymphoid cells: effect on the lymph nodes of euthymic and athymic mice. Allerg. Immunol. (Leipz.), 1977, v. 23, № 4, p. 287-294.
  25. Ladanyi A., Somlai B., Gilde K. et al. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin. Cancer. Res., 2004, v. 10, № 2, p. 521-530.
  26. Loyer E., David C., Sella A. and Ellerhorst J. Hyperplasia of axillary nodes in patients undergoing immunotherapy. Am. J. Roentgenol., 1997, v. 169, № 5, p. 1359-1362.
  27. Maurer T. and Kimber I. Draining lymph node cell activation in guinea pigs: comparisons with the murine local lymph node assay. Toxicology., 1991, v. 69, № 2, p. 209-218.
  28. McCulloch P., Gallagher G., Walsh L.P. et al. Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cellmediated immune response. Clin. Exp. Immunol., 1991, v. 85, № 3, p. 519-524.
  29. Meneses A., Verastegui E., Barrera J.L. et al. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2. Int. Immunopharmacol., 2003, v. 3, № 8, p. 1083-1091.
  30. Migliorati G., Nicoletti I., Nocentini G. et al. Dexamethasone and interleukins modulate apoptosis of murine thymocytes and peripheral T-lymphocytes. Pharmacol. Res., 1994, v. 30, № 1, p. 43-52.
  31. Mor F. and Cohen I.R. IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. Correlation with induction of Bcl-2. J. Immunol., 1996, v. 156, № 2, p. 515-522.
  32. Mukherji B., Guha A., Loomis R. and Ergin M.T. Cell-mediated amplification and down regulation of cytotoxic immune response against autologous human cancer. J. Immunol., 1987, v. 138, № 6, p. 1987-1991.
  33. Nakashima M., Janiszewska M,. Steplewski Z. et al. Proliferation, phenotype, and cytotoxicity of human lymphocytes isolated from lymph nodes invaded by melanoma cells. Hybridoma., 1994, v. 13, № 3, p. 241-246.
  34. Nguyen C.L., Salem M.L., Rubinstein M.P. et al. Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine, 2003, v. 21, № 19-20, p. 2318-2328.
  35. Nishimura T., Kozutsumi H. and Hashimoto Y. Mitogenic effect of IL 2 on non-thymic and thymic lymphocytes of the mouse. Thymus, 1984, v. 6, № 4, p. 225-233.
  36. Pierce V.E.Jr., Pantazis C.G. and Ades E.W. Examination of differentiation, proliferation and distribution of lymphoid cells in mice by immunohistochemical analysis post in vivo administration of recombinant interleukin-II. J. Clin. Lab. Immunol., 1988, v. 25, № 1, p. 47-52.
  37. Piguet P.F., Grau G., Irle C. and Vassalli P. Administration of recombinant interleukin 2 to mice enhances production of hemopoietic and natural killer cells. Eur. J. Immunol., 1986, v. 16, № 10, p. 1257-1261.
  38. Poudrier J. and Owens T. Th1 and Th2 help for B cells: differential capacity for induction of autonomous responsiveness to IL-2. Int. Immunol., 1995, v. 7, № 6, p. 1021-1027.
  39. Quan W.D.Jr., Walker P.R., Quan F.M. et al. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. Cancer Biother. Radiopharm., 2006, v. 21, № 5, p. 437-442.
  40. Reddy J., Chastagner P., Fiette L. et al. IL-2-induced tumor necrosis factor (TNF)-beta expression: further analysis in the IL-2 knockout model, and comparison with TNF-alpha, lymphotoxin-beta, TNFR1 and TNFR2 modulation. Int. Immunol., 2001, v. 13, № 2, p. 135-147.
  41. Shimonkevitz R.P., Husmann L.A., Bevan M.J. and Crispe I.N. Transient expression of IL-2 receptor precedes the differentiation of immature thymocytes. Nature, 1987, v. 329, № 6135, p. 157-159.
  42. Spieker-Polet H., Yam P.C., Arbieva Z. et al. In vitro induction of the expression of multiple IgA isotype genes in rabbit B cells by TGF-beta and IL-2. J. Immunol., 1999, v. 162, № 9, p. 5380-5388.
  43. Takacs L., Osawa H., Toro I. and Diamantstein T. Immunohistochemical localization of cells reacting with monoclonal antibodies directed against the interleukin-2 receptor of murine, rat and human origin. Clin. Exp. Immunol., 1985, v. 59, № 1, p. 37-44.
  44. Takenoyama M., Yasumoto K., Harada M. et al. Antitumor response of regional lymph node lymphocytes in human lung cancer. Cancer Immunol. Immunother., 1998, v. 47, № 4, p. 213-220.
  45. Teh H.S. and Yu M. Activation of nonspecific killer cells by interleukin 2-containing supernatants. J. Immunol., 1983, v. 131, № 4, p. 1827-1833.
  46. Vohr H.W. and Hunig T. Induction of proliferative and cytotoxic responses in resting Lyt-2+ T cells with lectin and recombinant interleukin 2. Eur. J. Immunol., 1985, v. 15, № 4, p. 332-337.
  47. Vujanovic N.L., Herberman R.B. and Hiserodt J.C. Lymphokineactivated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity. Cancer Res., 1988, v. 48, № 4, p. 878-883.
  48. Wen D.R., Hoon D.S., Chang C. and Cochran A.J. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol. Immunother., 1989, v. 30, № 5, p. 277-282.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 0110212 от 08.02.1993.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies